S/GSK1349572: Phase III started

Shionogi and ViiV Healthcare LLC, a JV between GlaxoSmithKline and Pfizer, began the double-blind, international Phase III SPRING-2 trial to compare once-daily 50 mg S/GSK1349572 vs. twice-daily 400 m...